MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.88 | 4.51 | 5.76 | 2.86 | 1.87 |
| CEPS(Rs) | 7.00 | 5.66 | 6.71 | 3.60 | 2.52 |
| DPS(Rs) | 0.50 | 0.25 | 0.25 | 0.10 | 0.05 |
| Book NAV/Share(Rs) | 38.51 | 27.10 | 21.66 | 15.54 | 13.25 |
| Tax Rate(%) | 21.42 | 24.52 | 21.06 | 23.17 | 22.88 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.64 | 16.71 | 24.40 | 16.95 | 13.21 |
| EBIT Margin(%) | 17.00 | 16.53 | 22.28 | 14.63 | 11.40 |
| Pre Tax Margin(%) | 16.56 | 15.98 | 21.71 | 13.86 | 10.43 |
| PAT Margin (%) | 13.01 | 12.06 | 17.14 | 10.65 | 8.04 |
| Cash Profit Margin (%) | 15.55 | 14.95 | 19.74 | 13.00 | 10.32 |
| Performance Ratios | |||||
| ROA(%) | 13.66 | 12.94 | 22.40 | 14.17 | 10.49 |
| ROE(%) | 18.59 | 18.72 | 31.33 | 20.49 | 15.88 |
| ROCE(%) | 22.89 | 23.82 | 39.76 | 25.57 | 18.51 |
| Asset Turnover(x) | 1.05 | 1.07 | 1.31 | 1.33 | 1.30 |
| Sales/Fixed Asset(x) | 2.62 | 2.42 | 2.49 | 2.12 | 2.00 |
| Working Capital/Sales(x) | 1.53 | 1.83 | 2.30 | 3.11 | 3.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.41 | 0.40 | 0.47 | 0.50 |
| Receivable days | 72.63 | 78.56 | 67.57 | 67.57 | 64.51 |
| Inventory Days | 81.36 | 97.65 | 84.73 | 86.10 | 93.32 |
| Payable days | 85.31 | 93.88 | 85.57 | 69.55 | 67.39 |
| Valuation Parameters | |||||
| PER(x) | 11.99 | 10.10 | 8.67 | 4.86 | 13.30 |
| PCE(x) | 10.07 | 8.05 | 7.44 | 3.86 | 9.85 |
| Price/Book(x) | 1.83 | 1.68 | 2.31 | 0.89 | 1.87 |
| Yield(%) | 0.71 | 0.55 | 0.50 | 0.72 | 0.20 |
| EV/Net Sales(x) | 1.36 | 1.04 | 1.35 | 0.44 | 1.08 |
| EV/Core EBITDA(x) | 6.32 | 5.18 | 5.35 | 2.57 | 7.92 |
| EV/EBIT(x) | 7.27 | 6.08 | 5.97 | 2.98 | 9.51 |
| EV/CE(x) | 1.13 | 0.94 | 1.51 | 0.55 | 1.35 |
| M Cap / Sales | 1.72 | 1.25 | 1.49 | 0.50 | 1.02 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 24.23 | 8.33 | 21.33 | 13.41 | 9.57 |
| Core EBITDA Growth(%) | 32.55 | -13.16 | 79.82 | 40.81 | 57.46 |
| EBIT Growth(%) | 35.48 | -17.47 | 86.93 | 45.59 | 89.88 |
| PAT Growth(%) | 42.02 | -21.68 | 97.54 | 50.12 | 124.68 |
| EPS Growth(%) | 30.32 | -21.77 | 101.63 | 53.05 | 132.12 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.02 | 0.03 | 0.18 |
| Current Ratio(x) | 4.65 | 3.22 | 3.02 | 2.59 | 2.28 |
| Quick Ratio(x) | 3.33 | 2.11 | 1.67 | 1.54 | 1.02 |
| Interest Cover(x) | 37.99 | 30.31 | 38.84 | 18.97 | 11.80 |
| Total Debt/Mcap(x) | 0.01 | 0.02 | 0.01 | 0.03 | 0.10 |
Compare Financial Ratios of peers of MARKSANS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MARKSANS PHARMA | ₹7,593.4 Cr | 0.4% | 10.6% | 104% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,315.0 Cr | -0.1% | -6.3% | 53.5% | Stock Analytics | |
| CIPLA | ₹114,614.0 Cr | 1% | -5% | 53.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹105,233.0 Cr | 3.2% | 15.3% | 23.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,900.0 Cr | 1.1% | 2.2% | 26% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹99,426.0 Cr | 3.9% | -1.7% | 85.2% | Stock Analytics | |
MARKSANS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | 0.4% |
10.6% |
104% |
| SENSEX | 1% |
2.2% |
23.7% |
You may also like the below Video Courses
